Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
Feature|Articles|July 7, 2026
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.
Advertisement
Advertisement
Artificial intelligence (AI) is rapidly moving beyond the realm of future promise and into everyday oncology practice. From enhancing surgical precision and diagnostic accuracy to refining biomarker-driven treatment selection and streamlining clinical trial enrollment, AI-powered tools are beginning to fundamentally reshape how cancer care is delivered.
Related to this article
Dana M. Chase, MD, joins Angeles Alvarez Secord, MD, MHSc, to discuss mocertatug rezetecan in gynecologic malignancies.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
Advertisement
Advertisement